ReviewCureus2026
A Systematic Review and Meta-Analysis Evaluating the Role of GLP-1 Receptor Agonists in Substance Use Disorders.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
GLP-1 receptor agonists (GLP-1RAs) have shown preclinical effects on reward-seeking behavior across several substance classes, but human randomized controlled trial (RCT) evidence remains limited. This systematic review and meta-analysis evaluated the effects of GLP-1RAs on substance-use outcomes in adults with substance use disorders. Electronic databases and trial registries were searched from inception to April 30, 2026, for parallel-group or crossover RCTs comparing any GLP-1RA with placebo or control. Outcomes included days without alcohol consumption, cigarettes smoked per day (CPD), and Fagerström Test for Nicotine Dependence (FTND) scores. Five RCTs met the inclusion criteria, including 764 participants with follow-up ranging from six to 52 weeks. Three RCTs contributed alcohol-related outcomes, and four contributed tobacco-related outcomes. Random-effects meta-analysis showed no statistically significant effect on days without alcohol consumption (MD -1.96 days, 95% CI -17.97 to 14.05; I² = 74%), CPD (MD -0.55 cigarettes/day, 95% CI -1.76 to 0.65; I² = 45%), or FTND score (MD 0.02, 95% CI -0.32 to 0.36; I² = 0%). Risk-of-bias assessment using the Cochrane Risk-of-Bias (RoB) 2 tool rated three trials as low risk overall and two as having some concerns. Certainty of evidence assessed using GRADE (Grading of Recommendations, Assessment, Development and Evaluations) ranged from low to moderate. Current pooled RCT evidence does not demonstrate a statistically significant benefit of GLP-1RAs for alcohol or tobacco use outcomes. A possible signal of benefit in patients with comorbid alcohol use disorder and obesity should be interpreted as hypothesis-generating because of the small number of trials, clinical heterogeneity, and imprecision. Adequately powered, long-duration, agent-specific RCTs using standardized substance-use outcomes are required before clinical translation can be recommended.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.